

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

App. No. : 10/061,128
Applicant : Schinazi *et al.*
Filed : January 30, 2002
TC/A.U. : 1637
Examiner : Jezia Riley

Confirmation No. 1763

Docket No. : 18085.105232 (EMU 2000 CIP)
Customer No. : 20786

RECEIVED

SEP 16 2003

TECHNOLOGY & INNOVATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,


Sherry M. Knowles
Reg. No. 33,052

Date: September 10, 2003
King & Spalding, LLP
191 Peachtree Street, N.E.
Atlanta, GA 30303
Office: (404)572-4600/ Fax: 404-572-5145
K&S Docket: 18085.105232 (EMU2000CIP)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 10, 2003.


Tisha Hardrick

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/061,128
Filing Date	January 30, 2002
First Named Inventor	Schinazi, <i>et al.</i>
Group Art Unit	1637
Examiner Name	Jezia Riley
Attorney Docket Number	18085.105232 EMU 2000 CIP

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	6,458,773	B1	GOSSELIN, <i>et al.</i>	10-01-2002	
	AB	6,407,077	B1	GOSSELIN, <i>et al.</i>	06-18-2002	
	AC	6,232,300	B1	SCHINAZI, <i>et al.</i>	05-15-2001	
	AD	6,147,058		YOSHIMURA, <i>et al.</i>	11-14-2000	
	AE	6,103,707		YAMADA, <i>et al.</i>	08-15-2000	
	AF	5,817,799		MARQUEZ, <i>et al.</i>	10-06-1998	
	AG	5,808,040		CHU, <i>et al.</i>	09-15-1998	
	AH	5,210,085		LIOTTA, <i>et al.</i>	05-11-1993	
	AI	4,908,440		STERZYCKI, <i>et al.</i>	03-13-1990	
	AJ	4,000,137		DVONCH, <i>et al.</i>	12-28-1976	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code (if known)				
	AK	EP	0,839,813	A1	Yamasa Corp.	05-06-1998		
	AL	EP	0,463,470	A2	Hoffman-LaRoche	01/02/1992		
	AM	EP	0,357,571	B1	Medivir Aktiebolag	04-03-1996		
	AN	EP	0,292,023	A2	Hoffman-LaRoche	05-24-1988		
	AO	WO	95/20595	A1	Univ. of Georgia Res. Found., & Yale Univ.	08/03/1995		
	AP	WO	94/14831	A1	Univ. of Alberta	07-07-1994		
	AQ	WO	92/08727	A1	Consig. Naz. Ricerche	05-29-1992		
	AR	WO	91/11186	A1	Emory University	08-08-1991		
	AS	WO	88/08001	A1	Aktiebolaget Astra	10-20-1988		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB-08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/061,128
Filing Date	January 30, 2002
First Named Inventor	Schinazi, <i>et al.</i>
Group Art Unit	1637
Examiner Name	Jezia Riley
Attorney Docket Number	18085.105232 EMU 2000 CIP

Sheet	2	of	2
-------	---	----	---

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BA	BOUFFARD, D.Y., <i>et al.</i> , "Kinetic Studies of 2',2'-Difluorodeoxycytidine (Gemcitabine) with Purified Human Deoxycytidine Kinase and Cytidine Deaminase," <i>Biochemical Pharmacology</i> , 45(9):1857-1861 (1993).	
	BB	JEONG, L.S., <i>et al.</i> , "Unanticipated Retention of Configuration in the DAST Fluorination of Deoxy-4'-thiopyrimidine Nucleosides with 'Up' Hydroxyl Groups," <i>Tetrahedron Letters</i> , 35(41):7569-7572 (1994).	
	BC	JEONG, L.S., <i>et al.</i> , "Facile Fluorination of Deoxy-4'-thiopyrimidine Nucleosides with 'Down' Hydroxyl Groups. Retention of Configuration After Fluoride Opening of the Quaternized N ³ -MFM Anhydronucleosides," <i>Tetrahedron Letters</i> , 35(41):7573-7576 (1994)	
	BD	MONTGOMERY, J.A., <i>et al.</i> , "9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)guanine: A Metabolically Stable Cytotoxic Analogue of 2'-Deoxyguanosine," <i>J. Med. Chem.</i> 29(11):2389-2392 (Nov. 1986).	
	BE	NIIHATA, S., <i>et al.</i> , "Synthesis of 2-Fluoro Sugar and Its Condensation Reaction with Silylated Thymine," <i>Bull. Chem. Soc. Jpn.</i> 68(5):1509-1512 (May 1995).	
	BF	OKABE, M., <i>et al.</i> , "Synthesis of 1-(2,3-Dideoxy-2-fluoro-β-D-threo-pentofuranosyl)cytosine (F-ddC). A Promising Agent for the Treatment of Acquired Immune Deficiency Syndrome," <i>J. Org. Chem.</i> 56:4392-4397 (Feb. 1991).	
	BG	VAN AERSCHOT, A., <i>et al.</i> , "3'-Fluoro-2',3'-dideoxy-5-chlorouridine: Most Selective Anti-HIV-1 Agent among a Series of New 2'- and 3'-Fluorinated 2',3'-Dideoxynucleoside Analogues," <i>J. Med. Chem.</i> 32(8):1743-1749 (August 1989).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED
SEP 10 2003
TECH CENTER 10/20/2003

CERTIFICATE OF MAILING

I hereby certify that this Response to the Office Action and Information Disclosure Statement dated March 10, 2003, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.



Tisha Hardrick

Date: September 10, 2003